Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 2/20 | 0.40 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.40 |
| ▸ | JAK3 | P52333 | 2/20 | 0.37 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.34 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.34 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.33 |
| ▸ | CDK2 | P24941 | 3/20 | 0.32 |
| ▸ | CDK1 | P06493 | 3/20 | 0.32 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.32 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.32 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.32 |
| ▸ | JAK2 | O60674 | 1/20 | 0.32 |
| ▸ | JAK1 | P23458 | 1/20 | 0.32 |
| ▸ | LOX | P28300 | 1/20 | 0.32 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.32 |
| ▸ | AXL | P30530 | 1/20 | 0.32 |
| ▸ | FLT3 | P36888 | 1/20 | 0.32 |
| ▸ | MERTK | Q12866 | 1/20 | 0.32 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.32 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL159110 | 0.77 | PDPK1 (0.50) | ADORA2ATLR7LRRK2CDK2CDK1 | |
| SCHEMBL453219 | 0.74 | ABL1 (0.34) | ADORA2AADORA2B | |
| SCHEMBL17800815 | 0.74 | PDE8B (0.35) | CDK2CDK1CCNB1CCNA2CCNA1 | |
| SCHEMBL8830357 | 0.73 | CDK2 (0.40) | JAK3LRRK2CDK2CDK1CCNB1 | |
| SCHEMBL3245634 | 0.73 | PDE8B (0.36) | CDK2CDK1CCNB1CCNA2CCNA1 | |
| SCHEMBL4144530 | 0.73 | CDK1 (0.38) | ADORA2AJAK3LRRK2CDK2CDK1 | |
| SCHEMBL27703108 | 0.72 | PARP1 (0.41) | CDK2CDK1CCNB1JAK2CCNB2 | |
| SCHEMBL3877942 | 0.72 | SMN1; SMN2 (0.38) | JAK3AXLFLT3MERTK | |
| SCHEMBL5033566 | 0.72 | ABL1 (0.33) | ADORA2AADORA2B | |
| SCHEMBL19539317 | 0.72 | ADORA2A (0.36) | ADORA2AADORA2BTLR7CDK2CDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10391166-B2 | Short oligonucleotides as vaccine adjuvants and therapeutic agents | SPRING BREAK PHARMACEUTICALS, INC. (US) | 2019-08-27 | — | — | US | disclosed |
| EP-3524252-A1 | DESIGN OF OLIGONUCLEOTIDE ANALOGS AS THERAPEUTIC AGENTS | Spring Bank Pharmaceuticals, Inc. (US) | 2019-08-14 | — | — | EP | disclosed |
| US-20150374816-A1 | DESIGN OF SHORT OLIGONUCLEOTIDES AS VACCINE ADJUVANTS AND THERAPEUTIC AGENTS | SPRING BANK PHARMACEUTICALS, INC. | 2015-12-31 | — | — | US | disclosed |
| EP-2956145-A2 | DESIGN OF SHORT OLIGONUCLEOTIDES AS VACCINE ADJUVANTS AND THERAPEUTIC AGENTS | Spring Bank Pharmaceuticals, Inc. (US) | 2015-12-23 | — | — | EP | disclosed |
| US-20150329864-A1 | DESIGN OF OLIGONUCLEOTIDE ANALOGS AS THERAPEUTIC AGENTS | SPRING BANK PHARMACEUTICALS, INC. (US) | 2015-11-19 | — | — | US | disclosed |
| US-9040234-B2 | Oligonucleotide analogs as therapeutic agents | SPRING BANK PHARMACEUTICALS, INC. (US) | 2015-05-26 | — | — | US | disclosed |
| WO-2014127378-A2 | DESIGN OF SHORT OLIGONUCLEOTIDES AS VACCINE ADJUVANTS AND THERAPEUTIC AGENTS | SPRING BANK PHARMACEUTICALS, INC. (US) | 2014-08-21 | — | — | WO | disclosed |
| EP-2611451-A2 | DESIGN OF OLIGONUCLEOTIDE ANALOGS AS THERAPEUTIC AGENTS | Spring Bank Pharmaceuticals, Inc. (US) | 2013-07-10 | — | — | EP | disclosed |
| WO-2012030626-A2 | DESIGN OF OLIGONUCLEOTIDE ANALOGS AS THERAPEUTIC AGENTS | SPRING BANK PHARMACEUTICALS, INC. (US) | 2012-03-08 | — | — | WO | disclosed |
| US-20120053226-A1 | DESIGN OF OLIGONUCLEOTIDE ANALOGS AS THERAPEUTIC AGENTS | SPRING BANK PHARMACEUTICALS, INC. (US) | 2012-03-01 | — | — | US | disclosed |
| US-20090048203-A1 | SUBSTITUTED ADENINES AND THE USES THEREOF | ASTRAZENECA AB (SE) | 2009-02-19 | — | — | US | disclosed |
| CN-101072787-A | Substituted adenines and the use thereof | ASTRAZENECA AB (SE) | 2007-11-14 | — | — | CN | disclosed |
| EP-1805196-A1 | SUBSTITUTED ADENINES AND THE USE THEREOF | AstraZeneca AB (SE) | 2007-07-11 | — | — | EP | disclosed |
| WO-2006040558-A1 | SUBSTITUTED ADENINES AND THE USE THEREOF | ASTRAZENECA AB (SE) | 2006-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048203-A1 | SUBSTITUTED ADENINES AND THE USES THEREOF | HPRT1, APRT, NUDT1 | ADORA2A 33/4885ADORA2B 46/4885JAK3 4139/4885 |
| US-20150374816-A1 | DESIGN OF SHORT OLIGONUCLEOTIDES AS VACCINE ADJUVANTS AND THERAPEUTIC AGENTS | TLR3, TLR5, TLR9 | ADORA2A 303/4885ADORA2B 384/4885JAK3 1487/4885 |
| US-10391166-B2 | Short oligonucleotides as vaccine adjuvants and therapeutic agents | TLR3, TLR5, TLR9 | ADORA2A 292/4885ADORA2B 388/4885JAK3 1469/4885 |
| US-20120053226-A1 | DESIGN OF OLIGONUCLEOTIDE ANALOGS AS THERAPEUTIC AGENTS | TLR3, TLR5, TLR9 | ADORA2A 281/4885ADORA2B 342/4885JAK3 249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.